Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Diabetes & Metabolism

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.diabet.2015.01.004PMID 25687901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Summary and discussion of “ The central role of the propensity score in observational studies for causal effects

  2014cited by this paper
• Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

  2013influential reference
• Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.

  2013cited by this paper
• Oxidative stress, anti‐oxidant therapies and chronic kidney disease

  2012cited by this paper
• Treating diabetes today with gliclazide MR: a matter of numbers

  2012cited by this paper
• Standards of Medical Care in Diabetes—2013

  2012cited by this paper
• Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.

  2012cited by this paper
• Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.

  2011cited by this paper
• Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.

  2011cited by this paper
• Of fads, fashion, surrogate endpoints and dual RAS blockade.

  2010cited by this paper
• The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy

  2010cited by this paper
• Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.

  2010cited by this paper
• A new equation to estimate glomerular filtration rate.

  2009cited by this paper
• Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

  2009cited by this paper
• Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

  2007cited by this paper
• The Association of Low Birthweight and Chronic Renal Failure among Medicaid Young Adults with Diabetes and/or Hypertension

  2006cited by this paper
• GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients

  2004cited by this paper
• Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet.

  2004cited by this paper
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

  2002cited by this paper
• Clinical practice. Nephropathy in patients with type 2 diabetes.

  2002cited by this paper
• Nephropathy in Patients with Type 2 Diabetes

  2002cited by this paper
• Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.

  2001cited by this paper
• Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.

  2000cited by this paper
• Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Gliclazide: a general free radical scavenger.

  1991cited by this paper

• Glimepiride & metformin FDC along with metformin + dapagliflozin + sitagliptin FDC in T2DM patients with high-risk CKD -Indian real world evidence study: GRACE CKD

  2025cites this paper
• Taking a Closer Look at Gliclazide – Benefits Beyond Glycemic Control

  2025cites this paper
• Efficacy and Safety of Gliclazide versus Glimepiride in T2DM Patients: A Systematic Review

  2025cites this paper
• Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus—Clinical Practice Position Statement of the Polish Society of Nephrology

  2024cites this paper
• The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus

  2024cites this paper
• Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach

  2023influential citation
• ADVANCE to ADVANCE-ON: Unfolding the "Legacy Story" in Diabetes.

  2023cites this paper
• Renal outcomes with sodium-glucose cotransporters 2 inhibitors

  2022cites this paper
• Role of Gliclazide in Safely Navigating Type 2 Diabetes Mellitus Patients Towards Euglycemia: Expert opinion from India

  2021cites this paper
• The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India

  2021cites this paper
• Association between blood urea nitrogen and incidence of type 2 diabetes mellitus in a Chinese population: a cohort study.

  2021cites this paper
• Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

  2021cites this paper
• Comparative effectiveness of cardiovascular, renal and safety outcomes of second‐line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta‐analysis of randomised controlled trials

  2021cites this paper
• Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

  2019cites this paper
• Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease

  2019cites this paper
• Sulfonylureas at the Glomerular Battlefield

  2018cites this paper
• Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies

  2017cites this paper
• Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide.

  2017cites this paper
• Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy.

  2017cites this paper
• Renal outcomes with dipeptidyl peptidase-4 inhibitors.

  2017cites this paper
• Is gliclazide a sulfonylurea with difference? A review in 2016

  2016cites this paper
• to cite Impact of Gliclazide Modified Release or Glimepiride as Add-on Therapy to Metformin on Glycemic and Oxidative Stress Parameters in Type 2 Diabetic Patients

  year unknowncites this paper